Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Early financials

<< Previous

Bullboard Posts

Next >>

Comment by Goaweighon Feb 12, 2021 6:13pm

174 Views

Post# 32559402

RE:RE:RE:RE:RE:RE:RE:Early financials

I'd rather take your word for it even if you're wrong... LOL !
Certain someone at ATE knows what to do or at least they know who to retain. !!

Pragmatist wrote:

Goaweigh wrote: Yes it is denominated in US $ and I noticed that but still wondered given that and the fact that we were in the process of co listing why we wouldn't create a Doc that would allow us to raise money in the US from the get go.
If we need a sponsorship to list, maybe from a Co. like Cowen, they may want to combine a listing with a raise if for no other reason than to collect a commission. Grease the wheels of commerce so to speak. So creating a US approved prospectus would get us that much closer, possibly. However I couldn't imagine that whatever info US regulators want could be that much differant than what we usually produce already so subject to a few tweeks it should be relatively easy to do as your post makes clear.
But still, why not just do it now ?
Anyway, thanks very much for the info, good to know.

Wondering if we do need a sponsor and who it might be, Cowen has a robust Healthcare practice and could provide instant buying power and market awareness.
We'll see soon I hope.

Pragmatist wrote: "The only head scratcher for me is our current shelf prospectus which doesn't qualify us to raise cash in the US but maybe we'll change that when we get approval and actually list. "

Canada and the US have a reciprocal agreement called the Multi-jurisdictional Disclosure System that allows Canadian companies to raise capital in the US markets using Canadian regulatory procedures (e.g., shelf prospectus). All Antibe has to do is apply. I believe the latest shelf was valued in US dollars.

https://www.osler.com/en/resources/cross-border/2020/raising-capital-in-the-united-states-a-canadian-company-s-guide-to-using-mjds-for-u-s-public-offer

I don't think that you need a sponsor. And I'm pretty sure that the company can use the Canadian prospectus as is without SEC review.

If you are interested in pursuing this and have several hours to kill, the 100 lb brick (reference) should provide an answer. Good Luck! :)